Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

177.28B

Market cap177.28B

Price-Earnings ratio

21.99

Price-Earnings ratio21.99

Dividend yield

2.23%

Dividend yield2.23%

Average volume

8.96M

Average volume8.96M

High today

$143.79

High today$143.79

Low today

$140.01

Low today$140.01

Open price

$141.05

Open price$141.05

Volume

6.90M

Volume6.90M

52 Week high

$143.80

52 Week high$143.80

52 Week low

$93.37

52 Week low$93.37

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $142.78, giving the company a market capitalization of 177.28B. It carries a P/E multiple of 21.99 and pays a dividend yield of 2.2%.

On 2026-02-03, Gilead Sciences(GILD) stock moved within a range of $140.01 to $143.79. With shares now at $142.78, the stock is trading +2.0% above its intraday low and -0.7% below the session's peak.

Trading volume for Gilead Sciences(GILD) stock has reached 6.9M, versus its average volume of 8.96M.

The stock's 52-week range extends from a low of $93.37 to a high of $143.80.

GILD News

Simply Wall St 2h

Gilead’s Growing Oncology Role Reshapes The Investment Case For GILD

Gilead Sciences (NasdaqGS:GILD) has expanded its oncology pipeline through a new licensing deal with Repare Therapeutics. Phase 3 data for Trodelvy combined wi...

Benzinga 17h

Synopsys, Rocket Companies, On Holding And A Health Care Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Hightower Advisors’ Stephanie Link picked Synopsys, Inc. (NASDAQ:SNPS) as her final trade. Sunnyvale, California-base...

Simply Wall St 2d

Did Trodelvy’s New Phase 3 Win in TNBC Just Shift Gilead Sciences' Investment Narrative?

Gilead Sciences recently reported in The New England Journal of Medicine that its Phase 3 ASCENT-04/KEYNOTE-D19 trial showed Trodelvy plus Keytruda improved pro...

Analyst ratings

74%

of 31 ratings

Buy

74.2%

Hold

22.6%

Sell

3.2%

More GILD News

Simply Wall St 4d

Gilead Sciences Valuation Check After Late Stage Oncology Wins And New HIV Prevention Launch

Gilead Sciences (GILD) is back in focus after positive Phase 3 ASCENT-04 data for Trodelvy plus Keytruda in metastatic triple-negative breast cancer, alongside...

Nasdaq 5d

March 13th Options Now Available For Gilead Sciences

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading today, for the March 13th expiration. At Stock Options Channel , our YieldBoost fo...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.